	US 12,145,983 B2
	Manufacturing methods for producing anti-TNF antibody compositions
Kristopher Barnthouse, Pottstown, PA (US); Subinay Ganguly, Newtown, PA (US); Maarten Groeneveld, Oegstgeest (NL); Manuel Lopez, Jr., Devon, PA (US); Michael Nedved, Downingtown, PA (US); and Kevin D. Smith, Philadelphia, PA (US)
Assigned to Janssen Biotech, Inc., Horsham, PA (US)
Appl. No. 17/438,702
Filed by Janssen Biotech, Inc., Horsham, PA (US)
PCT Filed Feb. 26, 2020, PCT No. PCT/IB2020/051634 § 371(c)(1), (2) Date Sep. 13, 2021, PCT Pub. No. WO2020/183269, PCT Pub. Date Sep. 17, 2020.
Claims priority of provisional application 62/818,341, filed on Mar. 14, 2019.
Prior Publication US 2022/0153830 A1, May 19, 2022
Int. Cl. C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01)

CPC C07K 16/241 (2013.01) [A61K 39/3955 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/41 (2013.01); C07K 2317/732 (2013.01); C07K 2317/90 (2013.01)]

12 Claims

1. Anti-TNF antibodies comprising: (i) a heavy chain comprising the amino acid sequence of SEQ ID NO:36; and (ii) a light chain comprising the amino acid sequence of SEQ ID NO:37, wherein the oligosaccharide profile of the anti-TNF antibodies comprises total neutral oligosaccharide species >99.0% and total charged oligosaccharide species <1.0%.